SLAM
TGTX icon

Swiss Life Asset Management’s TG Therapeutics TGTX Stock Holding History

Swiss Life Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$490K Sell
8,920
-1,193
-12% -$48.8K ﹤0.01% 969
2026
Q1 		$336K Buy
10,113
+3,172
+46% +$94.5K ﹤0.01% 1071
2025
Q4 		$207K Hold
6,941
– – ﹤0.01% 1265
2025
Q3 		$251K Buy
+6,941
New +$229K ﹤0.01% 1005

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swiss Life Asset Management's TGTX Position: Q2 2026 in Review

Swiss Life Asset Management reduced its TG Therapeutics (TGTX) stake by 12% in Q2 2026, selling an estimated $48.8K and leaving 8,920 shares worth $490K. The position accounts for ﹤0.01% of the portfolio, ranked #969.

Swiss Life Asset Management first reported a position in TGTX in Q3 2025 and has held it in 4 quarters since. 300 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Swiss Life Asset Management held 8,920 shares of TG Therapeutics worth $490K as of Q2 2026.
  • Swiss Life Asset Management sold 1,193 TG Therapeutics shares in Q2 2026, an estimated $48.8K.
  • TG Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #969 holding.
  • Swiss Life Asset Management first reported a position in TG Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 300 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.